What is Glycotest?
Glycotest Diagnostics operates at the intersection of biotechnology and oncology, specializing in the development of non-invasive blood-based assays for the early detection of liver cancer, fibrosis, and cirrhosis. By leveraging proprietary biomarker panels and sophisticated diagnostic algorithms, the company addresses a critical gap in the management of chronic liver conditions, including viral hepatitis and metabolic diseases. Their technology is designed to integrate seamlessly into standard clinical workflows, offering a scalable alternative to traditional, more invasive diagnostic procedures. By focusing on early intervention, Glycotest aims to significantly improve patient survival rates and reduce the long-term economic burden of liver-related mortality on healthcare systems worldwide.
How much funding has Glycotest raised?
Glycotest has raised a total of $13.2M across 2 funding rounds:
Series A
$10M
Private Equity
$3.2M
Series A (2018): $10M with participation from Shanghai Fosun Pharmaceutical Co. , Ltd. and Fosun Pharmaceutical Co.
Private Equity (2026): $3.2M, investors not publicly disclosed
Key Investors in Glycotest
Shanghai Fosun Pharmaceutical Co., Ltd.
A global healthcare group with a deep focus on pharmaceutical manufacturing, R&D, and medical device distribution.
Fosun Pharmaceutical Co.
A leading Chinese pharmaceutical conglomerate specializing in innovative drug development and healthcare services.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Glycotest?
With the recent capital injection, Glycotest is well-positioned to advance its clinical validation studies and expand its commercial footprint. The strategic focus will likely shift toward securing regulatory approvals in key international markets and enhancing the sensitivity of its algorithm-driven biomarker panels. As the company scales, it will prioritize the integration of its diagnostic solutions into large-scale hospital networks and diagnostic laboratories. This phase of growth is critical for establishing Glycotest as a standard-of-care provider in the hepatology space, ultimately driving long-term value for stakeholders while addressing one of the most pressing challenges in modern oncology.
See full Glycotest company page
